Article
Oncology
Sarah A. Limbacher, Susan R. Mazanec, Jennifer M. Frame, Mary C. Connolly, Sumin Park, Margaret Q. Rosenzweig
Summary: This study analyzed transcripts from clinical encounters of women receiving chemotherapy treatment for breast cancer to examine patient and provider interactions regarding menopausal symptom experience and management. The findings suggest a discordance in goals between patients and clinicians during the clinical visit. Women were often unprepared for the menopausal symptom experience, and clinicians did not frequently provide appropriate management or empathetic responses. These results highlight the importance of improving assessment and communication regarding menopausal symptoms in the clinical setting.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Medicine, General & Internal
Yunan Han, Justin Xavier Moore, Graham A. Colditz, Adetunji T. Toriola
Summary: This study investigated the association between family history of breast cancer (FHBC) and mammographic breast density in premenopausal women. The results showed a positive correlation between FHBC and breast density, suggesting a heritable component of mammographic breast density. This highlights the importance of early annual screening for premenopausal women with a family history of breast cancer.
Review
Oncology
Paulina E. Galavis, Camille Hardy Abeloos, Pine C. Cheng, Christine Hitchen, Allison McCarthy, Juhi M. Purswani, Bhartesh Shah, Sameer Taneja, Naamit K. Gerber
Summary: This paper provides a review on the existing data, delivery techniques, and ongoing research of APBI, aiming to better define patient selection, treatment delivery, dosimetric considerations, and toxicity outcomes.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Ke-Da Yu, Jing-Yu Ge, Xi-Yu Liu, Miao Mo, Min He, Zhi-Ming Shao
Summary: This study investigated the impact of a cyclophosphamide-free chemotherapy regimen on menstrual resumption and survival outcomes, finding that the regimen may increase the likelihood of menstrual resumption but did not significantly affect 5-year disease-free survival rates.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2021)
Article
Oncology
Jenny Furlanetto, Frederik Marme, Sabine Seiler, Christian Thode, Michael Untch, Sabine Schmatloch, Andreas Schneeweiss, Martina Bassy, Peter A. Fasching, Dominika Strik, Elmar Stickeler, Christian Schem, Thomas Karn, Eva-Maria Grischke, Carsten Denkert, Marion van Mackelenbergh, Volkmar Mueller, Valentina Nekljudova, Sibylle Loibl
Summary: In young women receiving chemotherapy for early breast cancer, a high proportion experienced chemotherapy-induced ovarian failure (CIOF) with most regaining premenopausal hormone levels within 2 years. CIOF was associated with better disease-free survival (DFS), especially in patients with hormone receptor-positive EBC or aged <30 years.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Medicine, General & Internal
Matteo Lambertini, Claudia Massarotti, Julie Havas, Barbara Pistilli, Anne-Laure Martin, Alexandra Jacquet, Charles Coutant, Florence Coussy, Asma Dhaini Merimeche, Florence Lerebours, Christine Rousset-Jablonski, Christelle Jouannaud, Olivier Rigal, Marion Fournier, Patrick Soulie, Maria Alice Franzoi, Lucia Del Mastro, Ann H. Partridge, Fabrice Andre, Ines Vaz-Luis, Antonio Di Meglio
Summary: As life expectancy increases for cancer patients, survivorship has become a crucial aspect of breast cancer care. Adequate contraceptive counseling is important for premenopausal breast cancer patients who do not wish to become pregnant. This study examined contraceptive use and methods in early breast cancer patients and identified factors associated with contraceptive use over time. The findings highlight the importance of raising awareness and providing targeted contraceptive counseling for premenopausal women with early breast cancer.
Article
Oncology
Meena S. Moran, A. Marilyn Leitch
Summary: The latest version of NCCN Guidelines for Breast Cancer provides numerous updated recommendations for the locoregional management of early-stage breast cancer, with a focus on axillary management, locoregional management after neoadjuvant therapy, and radiation delivery. The guidelines now separate recommendations for axillary staging based on whether patients have undergone breast-conserving surgery or mastectomy. The section on locoregional treatment after neoadjuvant therapy has been reformatted, reflecting the evolving optimal management for this patient group. Lastly, there are updated specifics regarding the delivery and sequencing of radiotherapy.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2022)
Article
Oncology
Oluchi Oke, Jiangong Niu, Mariana Chavez-MacGregor, Hui Zhao, Sharon H. Giordano
Summary: The study found a high rate of tamoxifen discontinuation among male breast cancer patients, with even among those continuing treatment a substantial number of non-adherent patients.
Article
Oncology
Martin C. Abba, Maria Laura Fabre, Jaeho Lee, Pradeep Tatineni, Hyunsuk Kil, C. Marcelo Aldaz
Summary: The long-non-coding HOX transcript antisense intergenic RNA (HOTAIR) is significantly upregulated in breast ductal carcinoma in situ (DCIS), promoting the progression of early-stage breast cancer by modulating multiple signaling pathways to induce premalignant phenotypic changes.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Patricia A. Ganz, Hanna Bandos, Charles E. Geyer, Andre Robidoux, Alexander H. G. Paterson, Jonathan Polikoff, Luis Baez-Diaz, Adam M. Brufsky, Louis Fehrenbacher, Ann W. Parsons, Patrick J. Ward, Louise Provencher, John T. Hamm, Philip J. Stella, Robert L. Carolla, Richard G. Margolese, Henry R. Shibata, Edith A. Perez, Norman Wolmark
Summary: This study compared the efficacy of AC and FEC-100 in the treatment of breast cancer. The results showed that the AC group had better quality of life during chemotherapy, while the FEC-100 group had a higher rate of amenorrhea. After 12 months of treatment, there were no significant differences in quality of life between the two groups.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
Letter
Medicine, General & Internal
Marie Fefferman, Kyra Nicholson, Kristine Kuchta, Catherine Pesce, Katherine Kopkash, Katharine Yao
Summary: This study builds on previous research to assess the ongoing increase in rates of bilateral mastectomy using the National Cancer Database.
Article
Cell Biology
Fangfang Duan, Muyi Zhong, Jinhui Ye, Li Wang, Chang Jiang, Zhongyu Yuan, Xiwen Bi, Jiajia Huang
Summary: This study explored the prognostic value of a novel comprehensive biomarker, the iron-monocyte-to-lymphocyte ratio (IronMLR) score, in patients with early-stage triple-negative breast cancer (TNBC). The study found that the IronMLR score was an independent predictor of disease-free survival (DFS) and overall survival (OS) in early-stage TNBC patients. A prognostic nomogram integrating the IronMLR score, T stage, and N stage was established to improve individualized survival predictions.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Oncology
Shambhavi Singh, Matthew D. Sutcliffe, Kathy Repich, Kristen A. Atkins, Jennifer A. Harvey, Kevin A. Janes
Summary: By combining stochastic profiling with 10-cell RNA sequencing, researchers identified a recurrent set of genes in luminal breast carcinoma cells, suggesting potential activation of pathways seen in other types of cancer.
Article
Oncology
Mihailo Miljanic, Chika Nwachukwu, Assal Rahimi
Summary: This case series and literature review suggest that definitive ablative radiation therapy may serve as a safe and effective treatment option for non-operable patients with early stage breast cancer. The observed durable treatment responses and minimal toxicity support the potential of this approach.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Mihailo Miljanic, Chika Nwachukwu, Assal Rahimi
Summary: This case series and literature review investigate the efficacy and safety of definitive ablative radiation therapy for non-operable patients with early stage breast cancer. The two cases presented demonstrate the potential of this approach to achieve durable responses.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)